Arcellx FY2026 EPS Estimate Increased by Leerink Partnrs

Arcellx, Inc. (NASDAQ:ACLX - Free Report) - Equities researchers at Leerink Partnrs raised their FY2026 EPS estimates for shares of Arcellx in a research note issued to investors on Wednesday, June 4th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will earn ($4.02) per share for the year, up from their prior forecast of ($4.21). The consensus estimate for Arcellx's current full-year earnings is ($1.58) per share. Leerink Partnrs also issued estimates for Arcellx's FY2027 earnings at ($2.46) EPS and FY2028 earnings at ($2.66) EPS.

Arcellx (NASDAQ:ACLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.29). The company had revenue of $8.13 million for the quarter, compared to the consensus estimate of $19.51 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%.

Separately, Scotiabank cut their target price on shares of Arcellx from $133.00 to $93.00 and set a "sector outperform" rating for the company in a research report on Friday, May 9th. Thirteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Arcellx has a consensus rating of "Buy" and an average price target of $111.33.

Arcellx Trading Up 1.2%

NASDAQ ACLX opened at $66.25 on Friday. Arcellx has a 1 year low of $47.86 and a 1 year high of $107.37. The stock's 50-day moving average price is $61.19 and its two-hundred day moving average price is $68.97. The company has a market cap of $3.65 billion, a PE ratio of -93.31 and a beta of 0.28.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ACLX. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Arcellx by 9.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,836 shares of the company's stock valued at $754,000 after purchasing an additional 858 shares during the period. Dimensional Fund Advisors LP increased its holdings in Arcellx by 156.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 305,088 shares of the company's stock worth $23,400,000 after purchasing an additional 186,013 shares in the last quarter. Millennium Management LLC boosted its holdings in Arcellx by 123.7% during the fourth quarter. Millennium Management LLC now owns 22,370 shares of the company's stock worth $1,716,000 after purchasing an additional 12,370 shares during the last quarter. Gilead Sciences Inc. purchased a new stake in shares of Arcellx during the fourth quarter valued at approximately $515,418,000. Finally, Invesco Ltd. raised its stake in shares of Arcellx by 15.7% during the 4th quarter. Invesco Ltd. now owns 26,550 shares of the company's stock worth $2,036,000 after purchasing an additional 3,610 shares during the period. Institutional investors own 96.03% of the company's stock.

Insiders Place Their Bets

In other Arcellx news, Director Kavita Patel sold 1,500 shares of the business's stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of $57.50, for a total transaction of $86,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 6,000 shares of company stock worth $377,655 in the last 90 days. Company insiders own 8.35% of the company's stock.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.